Management

Dr Erik Digman Wiklund
Dr Erik Digman Wiklund
Chief Executive Officer
Close
Dr Erik Digman Wiklund
Dr Erik Digman Wiklund
Chief Executive Officer

Former consultant in the Pharma & Healthcare practice of McKinsey & Company, combined with a PhD in cancer research.

Erik Digman Wiklund was hired as the Company’s CFO in April 2017, and transitioned into the CBO role in October 2018. In October 2021 he was appointed CEO of Targovax. Dr Wiklund previously worked for the Norwegian cancer biotechnology company Algeta ASA and the nutraceutical company Aker Biomarine Antarctic AS. He also has management consulting experience from the Pharma & Health Care practice of McKinsey & Company. Dr Wiklund holds a PhD in Molecular Biology from Aarhus University, Denmark, and the Garvan Institute of Medical Research in Sydney, Australia. Dr Wiklund is a Swedish and Norwegian citizen, residing in Norway.

Shares 100,000
Share options 1,200,000

 

Dr Lone Ottesen
Dr Lone Ottesen
Chief Medical Officer
Close
Dr Lone Ottesen
Dr Lone Ottesen
Chief Medical Officer

Dr Ottesen is a highly experienced drug developer with extensive experience across the global oncology and immune-oncology drug development spectrum with nearly 20 years in the pharmaceutical industry in both early- and late-phase development. Lone got her MD and PhD at Aarhus University in Denmark and has held roles of increasing seniority in GSK, Eisai and latest AstraZeneca where she was the Global Clinical Head for two assets in pivotal clinical development as well as leading the development of durvalumab in breast and gynecological cancers. Lone joined Targovax as Chief Development officer, and transitioned to Chief Medical Officer in 2022. Lone is the medical and clinical head for all Targovax Clinical Development activities across the portfolio.

Shares 47000
Share options 490,000
Dr Victor Levitsky
Dr Victor Levitsky
Chief Scientific Officer
Close
Dr Victor Levitsky
Dr Victor Levitsky
Chief Scientific Officer

Dr Levitsky is a seasoned internationally recognized expert in immunology, oncology, T-cell immunotherapy and immuno-oncology with in-depth knowledge of preclinical, translational and early stage clinical drug development. He brings extensive experience in pre-clinical drug development of protein-based biologics and small molecules. Dr Levitsky is a medical doctor with a PhD in Virology and post-doctoral training in tumor biology at Karolinska Institute, Sweden. He spent the first 20 years of his career as an academic research scientist, including Associate Professor positions at the Karolinska Institute in Sweden and the Johns Hopkins University School of Medicine in the USA. Before joining Targovax Dr Levitsky served as Tumor Immunology Leader and Senior Principal Scientist with Roche in Zurich, and his most recent position has been VP, Head of Oncology Research at Molecular Partners, Zurich, Switzerland. Dr Levitsky is a Swedish and Russian citizen and resides in Switzerland.

Shares 10,000
Share options 545,000
Ola Melin
Ola Melin
Head of Manufacturing
Close
Ola Melin
Ola Melin
Head of Manufacturing

With over 25 years’ experience in Biologics development, manufacturing and supply 

Ola Melin joins Targovax with over 25 years’ experience in Biologics development, manufacturing, and supply, most recently as Director of Technical Operations at OxThera AB, where he was responsible for clinical supply and for establishing a commercially ready manufacturing process and supply chain. Prior to that Ola spent eighteen years at Biovitrum and Sobi AB, where he held senior leadership roles as Head of External Manufacturing and Head of Product Supply, as well as other CMC positions. Ola started his career with manufacturing process development at Pharmacia. Ola has studied Biochemical engineering at Mälardalen University.

Shares 50,000
Share options 325,000
Dr Ingunn Munch Lindvig
Dr Ingunn Munch Lindvig
VP, Regulatory Affairs
Close
Dr Ingunn Munch Lindvig
Dr Ingunn Munch Lindvig
VP, Regulatory Affairs

Extensive experience with regulatory strategy and more than 20 years in the pharma and biotech industry

Ingunn Munch Lindvig has more than 20 years in the pharma and biotech industry. She has extensive experience with regulatory strategy and delivery on regulatory plans across a range of pharmaceutical products. Prior to joining Targovax Dr Lindvig was Head of Regulatory Affairs at Nordic Nanovector ASA for five years and she also led the regulatory function at Photocure ASA for seven years. Dr Lindvig was part of the Regulatory team at Nycomed Imaging/Nycomed Amersham/GE Healthcare.

Dr Lindvig holds a PhD in physiology from University of Oslo, Norway.  She is a Norwegian citizen and resides in Norway.

Shares 10,000
Share options 392,000
Dr Lubor Gaal
Dr Lubor Gaal
Chief Financial Officer
Close
Dr Lubor Gaal
Dr Lubor Gaal
Chief Financial Officer

Dr Lubor Gaal is a seasoned industry executive with 25 years of experience working in large pharmaceutical and biotechnology companies in Europe and the USA.

Most recently, he served as Managing Director and Head of Europe at Locust Walk, a global life science boutique investment bank. At Locust Walk, Dr Gaal was responsible for overseeing all European strategic transactions, including financings, M&A and licensing. Before Locust Walk, he was Head of External Innovation and Licensing and a member of the R&D Management Committee at Almirall and Head of Europe Search and Evaluation for oncology at Bristol-Myers Squibb. Prior to that, Dr Gaal held executive management positions at Neuro3d and Vectron Therapeutics, and global business development roles in Bayer. Dr Gaal has a Ph.D. in molecular and cell biology from the University of California at Berkeley, USA.

In Targovax, Dr Gaal´s core responsibilities will be to oversee all financial, investor relations and business development activities, as well as playing an integral role in defining and executing the corporate strategy.

Shares
Share options 300 000